ACM-001 is under clinical development by Actimed Therapeutics and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.
According to GlobalData, the latest event to affect ACM-001’s likelihood of approval (LoA) and phase transition for Cancer Anorexia-Cachexia Syndrome took place on 10 May 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway.
GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their ACM-001 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.
Espindolol (ACM-001) is under development for the treatment of cachexia related to stage III and IV non-small cell lung cancer, colorectal cancer and muscle weakness due to muscle weakness. It is administered orally as a tablet. It is a dual action anabolic catabolic transforming agent (ACTA). The drug candidate targets 5-HT1A, adrenergic beta-1 and beta-2 receptor. It was also under development for the treatment of sarcopenia.
Actimed Therapeutics overview
Actimed Therapeutics is a clinical-stage biopharmaceutical business focusing on bringing innovation to the treatment of muscle wasting diseases in order to revolutionise the care of a vulnerable patient group. The company is headquartered in United Kingdom.
Quick View ACM-001 LOA Data
|Highest Development Stage|